MARKET

AKER

AKER

Akers
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.410
-0.120
-3.40%
After Hours: 3.220 -0.19 -5.57% 17:53 02/25 EST
OPEN
3.670
PREV CLOSE
3.530
HIGH
3.680
LOW
3.330
VOLUME
325.15K
TURNOVER
--
52 WEEK HIGH
8.85
52 WEEK LOW
1.550
MARKET CAP
30.21M
P/E (TTM)
-1.1933
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
STOCKHOLDER ALERT: Monteverde & Associates Continues to Investigate the Following Merger
NEW YORK, NY / ACCESSWIRE / February 24, 2021 /Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm rated Top 50 in the 2018 and 2019 ISS Securities Class Action Services Report and headquartered at the Em...
ACCESSWIRE · 1d ago
Akers Biosciences' Proposed Partner MyMD's Lead Candidate Inhibits Fibrotic Diseases-Associated Biomarkers
Benzinga · 2d ago
Aker Biosciences Merger Partner MyMD Pharmaceuticals Highlights New Data On Its Lead Compound MYMD-1 From Phenotypic Study Performed By Eurofins Discovery
Data from the translationally relevant study reported ability of MYMD-1 to inhibit key biomarkers associated with fibrotic diseases including idiopathic pulmonary fibrosis (IPF) and interstitial lung disease
Benzinga · 2d ago
MyMD Pharmaceuticals Announces New Data on Its Lead Compound MYMD-1 from a Phenotypic Study Performed by Eurofins Discovery
Akers Biosciences, Inc. (Nasdaq: AKER), with its proposed merger partner MyMD Pharmaceuticals, Inc. ("MyMD"), a clinical stage pharmaceutical company committed to extending healthy lifespan by focusing on developing two therapeutic platforms, today announc...
BusinessWire · 2d ago
Study Identifies Effects of Temperature Changes on SARS-CoV-2 Transmission
Akers Biosciences, Inc. (Nasdaq: AKER), with its proposed merger partner MyMD Pharmaceuticals, Inc. ("MyMD"), a clinical stage pharmaceutical company committed to extending healthy lifespan by focusing on developing two therapeutic platforms, today announc...
Business Wire · 02/18 14:00
Akers Biosciences Responds to Erroneous Earnings Call Press Release
Akers Biosciences, Inc. (the "Company") (NASDAQ: AKER) confirmed that a press release issued earlier today with respect to an earnings call by Aker ASA was issued by a company wholly unrelated to the Company. The press release was errantly issued by the ne...
Business Wire · 02/17 18:45
Onconova Therapeutics, Processa Pharmaceuticals leads healthcare gainers; Interpace Biosciences, AIkido Pharma among major losers
Gainers: Onconova Therapeutics (ONTX) +29%, Processa Pharmaceuticals (PCSA) +26%, AnPac Bio-Medical Science ANPC +25%, Oncolytics Biotech ONCY +22%, Cleveland BioLabs (CBLI) +15%.Losers: Interpace Biosciences IDXG -24%, AIkido Pharma AIKI -24%, Akers Biosc...
Seekingalpha · 02/17 15:57
Aker ASA to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / February 17, 2021 / Aker ASA (NASDAQ:AKER) will be discussing their earnings results in their 2020 Fourth Quarter Earnings call to be held on February 17, 2021 at 9:00 AM Eastern Time.To listen to the event live or .
ACCESSWIRE · 02/17 11:45
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of AKER. Analyze the recent business situations of Akers through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average AKER stock price target is 4.000 with a high estimate of 4.000 and a low estimate of 4.000.
EPS
Institutional Holdings
Institutions: 37
Institutional Holdings: 1.15M
% Owned: 12.96%
Shares Outstanding: 8.86M
TypeInstitutionsShares
Increased
3
44.95K
New
8
547.24K
Decreased
4
17.30K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Medical Equipment, Supplies & Distribution
-1.55%
Healthcare Equipment & Supplies
-1.74%
Key Executives
Chairman/Director
Joshua Silverman
President/Chief Executive Officer
Christopher Schreiber
Chief Executive Officer/Director
.. Gormally
Chief Financial Officer
Ian Rhodes
Independent Director
Robert Schroeder
Independent Director
Bill White
  • Dividends
  • Splits
  • Insider Activity
No Data
  • All
  • Financials
  • Insiders
More
About AKER
Akers Biosciences, Inc. develops, manufactures, and supplies point-of-care screening and testing products designed to bring health-related information directly to the patient or clinician. The Company’s product offerings focus on delivering diagnostic assistance in a variety of healthcare fields/specialties, including diagnostic rapid manual point-of-care tests for the detection of allergic reactions to Heparin and for on- and off-the-job alcohol safety initiatives. The Company's primary focus is on the development and sale of disposable diagnostic testing devices that can be performed in minutes, to facilitate time sensitive therapeutic decisions. The Company's main products include a disposable breathalyzer test that measures the blood alcohol content of the user, a rapid test detecting the antibody causing an allergic reaction to Heparin and a disposable breathalyzer test that measures Free Radical activity in the human body.

Webull offers kinds of Akers Biosciences Inc stock information, including NASDAQ:AKER real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AKER stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading AKER stock methods without spending real money on the virtual paper trading platform.